Back to Agenda
The Promise of Disease Progression Modeling to Bring Treatments to Patients Sooner
Session Chair(s)
Summer Starling, DrPH, MPH
Senior Project Manager
Clinical Trials Transformation Initiative (CTTI), United States
The impact of disease progression modeling (DPM) on medical product development has yet to be fully realized. This forum will describe DPM and its current applications in clinical trials and highlight the value of DPM to advance decision making and clinical development efficiency.
Learning Objective : Describe disease progression modeling (DPM) and its current applications in clinical trials; Define the value of DPM to enhance decision making throughout the medical product development lifecycle; Discuss multi-stakeholder effort to advance clinical trial and medical product development efficiency through the increased recognition, value, and consistent use of DPM.
Speaker(s)
Panelist
Emmanuel Chigutsa
Lilly, United States
Executive Director, Pharmacometrics
Panelist
Herbert Pang, PhD, MBA
Genentech, A Member of the Roche Group, United States
Expert Statistical Scientist
Panelist
Karthik Venkatakrishnan, PhD
EMD Serono, United States
Vice President, Global Head of Quantitative Pharmacology
Speaker
Philip John Green
CTTI, United States
Steering Committee Patient Representative
Have an account?